The biological problem the researchers set out to tackle is well known to reproductive medicine. As women age, the quality of their oocytes deteriorates, driving up rates of miscarriage, chromosomal abnormalities, preterm birth and fetal growth restriction, and making women aged 35 to 39 more prone to infertility than any other age group. Oocyte quality hinges on two tightly coordinated processes: nuclear maturation, in which chromosomes separate during the resumption of meiosis, and cytoplasmic maturation, in which the egg stockpiles the messenger RNAs, proteins and substrates that fertilization and early embryonic development will demand. Aging disrupts the cytoplasmic arm of this program through mitochondrial dysfunction, disturbed calcium signaling, malformed smooth endoplasmic reticulum and cytoskeletal disarray.

Mitochondria sit at the center of that failure. The oocyte is one of the most energy-hungry cells in the body, relying on oxidative phosphorylation through the five complexes of the electron transport chain to power chromosome segregation, spindle migration and organelle repositioning. In aging oocytes, the respiratory capacity of each mitochondrion falls and the mitochondrial membrane potential drops, a shift typically accompanied by a surge in reactive oxygen species. That oxidative burst damages nuclear and mitochondrial DNA, destabilizes the meiotic spindle and can ultimately produce aneuploid eggs. Previous metabolic surveys of aging ovaries found depletion of NAD+, purines and pyrimidines alongside an accumulation of glycolysis substrates and glutamine, painting a consistent picture of failing mitochondrial metabolism.

Researchers have tried a succession of interventions to prop up the aging egg: the CD38 inhibitor 78c to raise NAD+ levels, rapamycin to restore protein homeostasis, melatonin to quench oxidative stress, spermidine to enhance mitophagy, and mitochondria-targeted antioxidants such as MitoQ and SkQ1, along with NAD+ boosters like nicotinamide mononucleotide and the electron carrier CoQ10. Each has shown promise, but low targeting efficiency and poor bioavailability have limited clinical translation. Elamipretide, a membrane-penetrating aromatic cationic tetrapeptide with the sequence Arg-Dmt-Lys-Phe-NH2, was attractive to the team precisely because it is small, water-soluble, resistant to peptidase degradation and stable in solution—properties that make it a plausible candidate for real-world clinical use.

The peptide’s mechanism is unusually specific. At physiological pH it carries three positive charges and accumulates in the inner mitochondrial membrane through electrostatic and hydrophobic interactions, where it binds with high affinity to cardiolipin, a signature phospholipid of that membrane. Cardiolipin is central to respiratory chain supercomplex assembly, membrane stability and energy transduction, but it is also vulnerable to oxidation under oxidative stress, which disrupts the membrane, saps electron transport efficiency and diminishes ATP output. By binding cardiolipin, elamipretide inhibits the peroxidase activity of cytochrome c, prevents cardiolipin oxidation and preserves the cristae architecture of the inner membrane, stabilizing energy production and cutting back the generation of reactive oxygen species.

To test whether these properties could rescue the aging ovary, the team treated 10-month-old mice—well past the mouse reproductive prime—with daily intraperitoneal injections at 3, 5 or 10 milligrams per kilogram. The 5 mg/kg dose proved optimal, and a seven-day course was the most effective duration, improving reproductive performance in 8-, 10- and 12-month-old animals with the strongest gains in the 10-month group. Ovarian sections showed a marked increase in high-quality dominant follicles, fertilization rates of aged oocytes rose substantially, and early embryonic development recovered: aged oocytes normally stall between the two-cell and four-cell stages after fertilization, but elamipretide effectively reversed that block. The benefit, however, was transient, lasting only about a month, which the authors note defines both the promise and the limits of the regimen.

Molecular profiling revealed an unexpected metabolic handle on the effect. Metabolomics of treated ovaries showed that elamipretide shifted the aged metabolome back toward a young-like profile, and pathway analysis singled out vitamin B6 metabolism as the most dramatically altered route. When the team supplemented aged oocytes directly, vitamin B6—but not the other strongly altered metabolites, L-acetylcarnitine and aminovaleric acid—fully reversed the age-associated decline in first polar body extrusion, the hallmark of successful nuclear maturation. Transcriptomics then pointed to the vascular endothelial growth factor pathway, whose age-elevated expression was normalized by the peptide. Blocking VEGF-A transcription with the inhibitor PTC299 reproduced many of elamipretide’s benefits in aged oocytes, restoring mitochondrial positioning, damping the ROS surge, repairing spindle defects and correcting chromosome misalignment, while PI3K/AKT inhibitors failed to do so—placing VEGF-A, acting downstream of vitamin B6 metabolism, at the heart of the mechanism.

Under the microscope, the cellular rescue was striking. Aged oocytes typically display aberrant spindles and scattered chromosomes, loss of γ-tubulin foci at the spindle poles, and reduced acetylation of tubulin, a marker of microtubule instability. Elamipretide restored all of these, along with the cytoplasmic actin network that aging disrupts, and it recovered the expression of ROCK1/2, proteins involved in actin assembly. Mitochondria, which drift away from the spindle and clump in the cytoplasm of aged eggs, returned to their proper peri-spindle domain; ATP levels normalized, mitochondrial DNA copy number partially rebounded, membrane potential rose and ROS fell. The peptide also repaired organelle systems beyond the mitochondria: Golgi markers Rab10 and GM130, endoplasmic reticulum positioning and the ER stress marker GRP78, lysosomal distribution and LC3-mediated autophagic flux all returned toward youthful patterns, indicating a coordinated restoration of cytoplasmic maturation.

Crucially, the findings were not confined to mice. In a randomized in vitro experiment approved under the Declaration of Helsinki, germinal vesicle oocytes from 39 patients undergoing intracytoplasmic sperm injection were cultured with or without 500 micromolar elamipretide. Among women aged 35 and older—three patients contributing 54 oocytes—the peptide improved maturation at both 24 and 48 hours and raised fertilization and cleavage rates after ICSI, with similar gains in younger women’s oocytes. In pigs, whose oocytes are a standard translational model, elamipretide at 1 millimolar rescued maturation in eggs subjected to hydrogen-peroxide-induced oxidative stress, restoring mitochondrial distribution, LC3 expression and apoptosis levels. The authors conclude that short-term elamipretide treatment reverses age-related oocyte decline through a vitamin B6–VEGF axis that jointly rescues nuclear and cytoplasmic maturation. Because the peptide has already advanced into human trials for cardiac and neuromuscular indications, the path from mouse ovary to fertility clinic may be shorter than for most laboratory discoveries—though the transient one-month window of benefit and the small human sample mean considerable work remains before any clinical application.

Subject of Research: Mitochondria-targeted peptide therapy for age-related decline in oocyte quality and female fertility

Article Title: Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging

Article References: Zhang, H.-L., Wang, Y., Wang, C., Guo, X., Chen, H., Hou, Y.-X., Wu, X., Wu, Z.-J., Pan, W.-L., Ma, R.-J., Lu, P.-S., Shu, J., & Sun, S.-C. (2026). Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging. Aging Cell, 25(10), Article e70749. https://doi.org/10.1111/acel.70749

Image Credits: AI Generated

DOI: 10.1111/acel.70749

Keywords: elamipretide, oocyte aging, female fertility, mitochondria, cardiolipin, vitamin B6, VEGF, oxidative stress, meiotic spindle, reproductive aging, in vitro maturation, Aging Cell

Premature ovarian insufficiency, or POI, affects a meaningful fraction of women of reproductive age and carries consequences that extend far beyond infertility. Women with the condition face elevated risks of osteoporosis, cardiovascular disease, and the psychological burden of an unexpectedly early menopause. A 2023 systematic review and meta-analysis cited in the study estimated the global prevalence of the disorder, and clinicians have struggled for years with the fact that most cases have no identifiable cause. Genetic abnormalities, chemotherapy, and autoimmune damage account for only a subset of diagnoses, leaving a large majority classified as idiopathic. That gap in understanding has pushed investigators toward environmental suspects, and among them one chemical has drawn particular attention: bisphenol A.

Bisphenol A, commonly abbreviated as BPA, is an industrial compound used in the manufacture of polycarbonate plastics and epoxy resins, which find their way into food containers, water bottles, thermal receipt paper, and countless everyday products. Because BPA can mimic estrogen in the body, it belongs to a class of substances called endocrine-disrupting chemicals, and it is so widespread in modern environments that measurable traces appear in the urine of most people tested. Prior research, including animal work showing that BPA can trigger premature activation of primordial follicles in mouse ovaries through the PTEN signaling pathway, has already linked the chemical to ovarian damage. Epidemiological studies have also associated urinary BPA concentrations with reduced antral follicle counts among women attending infertility clinics. What remained unclear was the precise molecular mechanism by which BPA might impair the ovarian cells responsible for supporting follicle development.

The research team, led by Erqiu Du and Wei Xu of Taizhou Central Hospital in Zhejiang Province, China, together with co-first author Jin Pan of Shaoxing University, approached this question from the angle of gene regulation. Their focus fell on microRNAs, tiny noncoding RNA fragments, typically around twenty-two nucleotides long, that act as post-transcriptional regulators. Rather than encoding proteins, these small molecules bind to complementary sequences in messenger RNAs and either block their translation into protein or mark them for degradation. A single microRNA can tune the expression of dozens of target genes, which makes them powerful control points in cellular processes, and previous studies have already identified altered microRNA profiles in the blood plasma of women with premature ovarian failure, including changes in molecules such as miR-23a and miR-22-3p.

To dissect the relationship among BPA, microRNAs, and cell cycle control, the investigators used cell culture and transfection techniques in the laboratory, exposing ovarian granulosa cells to BPA and measuring the consequences for cell proliferation. Granulosa cells are the somatic cells that surround developing oocytes within follicles, and their healthy proliferation is essential for follicular growth, ovulation, and the production of hormones that sustain the menstrual cycle. Because these cells must divide in a tightly coordinated fashion as follicles mature, any interference with their cell cycle machinery can ripple outward into compromised ovarian function. The team employed quantitative real-time polymerase chain reaction to quantify microRNA expression levels and Western blotting to assess protein abundance, providing complementary molecular readouts of what BPA was doing inside the cells.

The results were consistent and revealing. BPA exposure significantly inhibited the proliferation of the granulosa cells, and that growth arrest was closely associated with two parallel molecular changes: an upregulation of specific microRNAs, prominently including miR-26a-3p, and a downregulation of the CCND1 protein. Cyclin D1 is a central figure in the G1 phase of the cell cycle, the interval during which a cell grows and prepares to duplicate its DNA. By partnering with cyclin-dependent kinases, Cyclin D1 helps push cells through the restriction point that commits them to division. When Cyclin D1 levels fall, cells stall before DNA replication, and tissue renewal slows. The correspondence between rising miR-26a-3p and falling CCND1 suggested to the researchers a direct regulatory relationship, consistent with the known capacity of microRNAs to suppress specific target transcripts.

Perhaps the most compelling evidence came from the team’s manipulation experiments. When the researchers artificially increased the levels of the identified microRNAs through transfection, the overexpression partially reversed the BPA-induced changes in CCND1 expression, supporting the idea that the microRNA sits upstream of the cell cycle protein in the pathway affected by BPA. In other words, the data fit a model in which BPA exposure raises miR-26a-3p abundance, which in turn suppresses CCND1, thereby throttling granulosa cell proliferation. While the word partially is important, since it indicates that other pathways likely operate alongside this one, the demonstration that a single microRNA can modulate the response to BPA offers a concrete mechanistic handle on what has been a murky problem.

The significance of this work lies in how it connects three previously separate threads: environmental exposure, small RNA regulation, and cell cycle control in the ovary. For years, studies of POI have documented associations between endocrine-disrupting chemicals and reproductive harm, and separate bodies of literature have catalogued microRNA alterations in ovarian disease. By placing miR-26a-3p and CCND1 in a single causal chain, the study supplies a plausible molecular bridge between the two. It also aligns with a broader shift in reproductive biology, in which noncoding RNAs are increasingly recognized as biomarkers and therapeutic targets in female infertility, a trend reflected in recent reviews of microRNAs in primary ovarian insufficiency and related conditions such as diminished ovarian reserve and poor ovarian response.

As with all cell culture studies, important caveats apply. The experiments were conducted entirely in vitro, without human participants, clinical trials, or animal studies, and the researchers note that ethics approval and participant consent were not applicable for that reason. Laboratory cell lines, even ones such as the well-characterized steroidogenic granulosa-like KGN line that expresses functional follicle-stimulating hormone receptors, cannot fully reproduce the complex hormonal and structural environment of a living ovary. Whether the BPA concentrations used in culture correspond meaningfully to real-world human exposure levels, and whether the same microRNA-protein axis operates in granulosa cells within intact follicles, will require further investigation in animal models and, eventually, human tissue studies. The authors themselves emphasize that future research should further elucidate the specific roles of these microRNAs and CCND1 in ovarian insufficiency and explore their potential application as therapeutic targets.

Even so, the findings arrive at a moment of mounting public concern about chemical exposures and fertility. Global prevalence estimates for premature ovarian insufficiency, together with rising attention to declining fertility across many countries, have intensified the search for modifiable risk factors. If a molecular pathway such as the miR-26a-3p and CCND1 axis proves robust in follow-up studies, it could open several doors at once: a biomarker signature for early detection of ovarian stress, a mechanistic test for screening suspected endocrine disruptors, and a target for interventions designed to protect granulosa cell function. The study was supported by the Zhejiang Provincial Basic Public Welfare Research Plan Project and related provincial health research programs, reflecting institutional investment in untangling the environmental roots of reproductive disease. For now, the image that lingers is a deceptively simple one: a ubiquitous plastic additive, a twenty-two-nucleotide RNA fragment, and a single cell cycle protein, locked together in a circuit that may help decide how long a woman’s ovaries keep working.

Subject of Research: MicroRNA-mediated regulation of Cyclin D1 in bisphenol A-associated premature ovarian insufficiency

Article Title: Possible Involvement of miR-26a-3p in Regulating Cyclin D1(CCND1) in the Pathogenesis of Premature Ovarian Insufficiency (POI)

Article References: Du, E., Pan, J., Zhang, L., & Xu, W. (2026). Possible Involvement of miR-26a-3p in Regulating Cyclin D1(CCND1) in the Pathogenesis of Premature Ovarian Insufficiency (POI). Reproductive Sciences. https://doi.org/10.1007/s43032-026-02218-0

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02218-0

Keywords: premature ovarian insufficiency, miR-26a-3p, Cyclin D1, CCND1, bisphenol A, granulosa cells, microRNA, endocrine disruptor, cell cycle, ovarian proliferation, reproductive sciences, female fertility